2 results
Approved WMOCompleted
The primary objective of the study is to evaluate the reduction of low density lipoprotein cholesterol (LDL-C) by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (heterozygous familial…
Approved WMOCompleted
This proof of concept study is to estimate the effect of SRCaBu (600 mg daily for four weeks) on compositional and functional characteristics of the microbiome for future sample size calculation.The secondary objectives: 1) To evaluate the short-…